Eagle Asset Management Inc. trimmed its position in Catalent Inc (NYSE:CTLT) by 30.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 411,309 shares of the company’s stock after selling 183,916 shares during the quarter. Eagle Asset Management Inc.’s holdings in Catalent were worth $19,602,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. increased its holdings in shares of Catalent by 2.8% in the 2nd quarter. BlackRock Inc. now owns 14,307,589 shares of the company’s stock valued at $775,615,000 after acquiring an additional 388,615 shares during the last quarter. Highline Capital Management L.P. acquired a new position in Catalent during the 2nd quarter worth $111,494,000. Invesco Ltd. boosted its position in Catalent by 11.9% during the 2nd quarter. Invesco Ltd. now owns 1,774,766 shares of the company’s stock worth $96,210,000 after acquiring an additional 188,998 shares during the period. Viking Global Investors LP boosted its position in Catalent by 50.5% during the 2nd quarter. Viking Global Investors LP now owns 1,595,579 shares of the company’s stock worth $86,496,000 after acquiring an additional 535,066 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in Catalent by 2.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,553,474 shares of the company’s stock worth $84,214,000 after acquiring an additional 32,691 shares during the period.
A number of analysts have recently commented on CTLT shares. Zacks Investment Research downgraded Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday, October 29th. Morgan Stanley boosted their price objective on Catalent from $50.00 to $61.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 28th. ValuEngine lowered Catalent from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Stephens assumed coverage on Catalent in a research report on Thursday, October 17th. They set an “overweight” rating and a $56.00 target price on the stock. Finally, Robert W. Baird boosted their target price on Catalent from $50.00 to $60.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $56.25.
NYSE:CTLT traded up $0.27 during trading hours on Friday, hitting $49.52. 467,188 shares of the company’s stock traded hands, compared to its average volume of 806,017. The firm has a market cap of $7.38 billion, a P/E ratio of 30.57, a P/E/G ratio of 2.47 and a beta of 1.69. Catalent Inc has a twelve month low of $29.23 and a twelve month high of $58.38. The company has a debt-to-equity ratio of 2.74, a quick ratio of 1.70 and a current ratio of 2.06. The stock’s fifty day moving average price is $49.09 and its two-hundred day moving average price is $50.57.
Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.07. The firm had revenue of $664.70 million for the quarter, compared to analyst estimates of $634.87 million. Catalent had a return on equity of 16.87% and a net margin of 5.77%. Catalent’s quarterly revenue was up 20.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.28 earnings per share. On average, equities research analysts predict that Catalent Inc will post 1.81 earnings per share for the current year.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: What are defining characteristics of a correction?
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.